Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768746 | 0.85 | MTNR1A (0.35) | TSHRMTNR1AMTNR1BMAPK1MAPT | |
| SCHEMBL5796602 | 0.85 | KDM4E (0.39) | MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL11744513 | 0.81 | ACHE (0.46) | ACHEHSD17B10TSHRPDK1PDK2 | |
| SCHEMBL1719811 | 0.80 | MTNR1A (0.51) | HSD17B10MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL5768646 | 0.77 | MTNR1A (0.47) | HSD17B10MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL5765711 | 0.72 | PARP1 (0.36) | MTNR1AMTNR1BMAPT | |
| SCHEMBL6334216 | 0.72 | BCL2 (0.38) | MTNR1AMTNR1BL3MBTL1ALDH1A1MAPT | |
| SCHEMBL2344849 | 0.72 | PARP1 (0.44) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL5768891 | 0.71 | MTNR1A (0.35) | MTNR1AMTNR1BALDH1A1MAPT | |
| SCHEMBL21941615 | 0.67 | GSK3B (0.37) | TSHRPDK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | ACHE 4882/4885HSD17B10 2105/4885TSHR 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.